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Hypercholesterolemia is a major cardiovascular risk factor. 
Type 2 diabetes patients tend to have high risk for cardiovascu-
lar disease not just due to hypercholesterolemia, but also due 
to dyslipidemia composed of hypertriglyceridemia and low 
high density cholesterol lipoprotein cholesterol (HDL-C) lev-
els caused by insulin resistance [1]. Hydroxymethylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitor (statin) is the 
drug of choice for the treatment of hypercholesterolemia. The 
American Diabetes Association recommends lowering low 
density lipoprotein cholesterol (LDL-C) levels to less than 100 
mg/dL in diabetes patients, preferably through statin adminis-
tration [2]. 
  In the last issue of Korean Diabetes J, Kim et al. [3] reported 
a retrospective study of the efficacy of 10 mg atorvastatin in 105 
Korean type 2 diabetes patients. They found that the response 
rate to 10 mg atorvastatin was 74.3% in the first 6 months of 
treatment, and that the response rates in three subgroups of 
responder groups divided by dosage were in compliance with 
the dosage. Interestingly, the average LDL-C levels and body 
mass indexes (BMIs) of the responder group were significantly 
lower than those of the non-responder group. In non-respond-
ers, when the dosage was doubled to 20 mg, the response rate 
increased from 28.6% to 50%. Kim et al. therefore found that 
10 mg atorvastatin, which is one of the most often prescribed 
statin dosage regimens in Koreans, significantly lowered LDL-
C levels in type 2 diabetes patients within 6 months. They 
showed that the baseline risk factors that correlated with the 
response were LDL-C levels and BMI, which supports reflects 
the association of obesity with statin response in their study 
sample. They also showed that the response rate for the 5-year 
follow-up period was 71.4% in a small proportion of the pa-
tients followed up, although the absolute number of patients 
was too small to draw any conclusions. 
  Although it yielded interesting results, the study by Kim et 
al. left several questions to be answered. First of all, their study 
lacks power because it did not include actual drug compliance 
in considerations of efficacy. This may decrease confidence re-
garding their results, since adherence and persistence are 
strongly associated with the effects of statin and hence, with 
clinical outcomes [4]. For example, in diabetes patients with 
and without cardiovascular disease, nonadherence (<80%) re-
sulted in significantly increased risks of hospitalization (odds 
ratio [OR], 1.39) and all-cause mortality (OR, 2.07) [5]. Not 
taking adherence and compliance into consideration makes 
the results of their study tenuous.
  Kim et al. recommended that although three quarters of 
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their patients showed efficacy under 10 mg fixed dose regimens 
of atorvastatin with lowered LDL-C levels in 6 months, signifi-
cant numbers of patients required higher starting and mainte-
nance dosages. As they mentioned in their discussion, phar-
macogenetic differences in drug response may exist between 
different populations. Asian patients frequently have height-
ened responses to therapeutic drugs [6]. As a consequence, 
recommended drug doses are often lower in Asian countries. 
Among the explanations cited as the reasons for the differenc-
es is their smaller body size; but body size appears to have little 
effect on statin response in Asians [7]. The results of Kim et al.’s 
study must be interpreted considering population-specific dif-
ferences in drug metabolism [6]. In addition, the size of the 
whole study sample was relatively small, and so was the num-
ber of patients followed up for 6 months. This could be one of 
the biggest pitfalls in making the conclusion from the study. 
The authors also did not consider switching to other statins as 
an alternative for non-responders. Certainly, structural differ-
ences in different statins affect their efficacy for the prevention 
of cardiovascular disease, since the LDL-C lowering effect is 
not the only anti-atherosclerotic effect of statin [8]. Before con-
sidering elevation of statin dosage in non-responders, these 
other factors should be considered.
  Another interesting result of Kim et al.’s study was that the 
average BMI of the responder group was significantly lower 
than that of the non-responder group. Several previous studies 
showed the effect of obesity on HDL-C levels [9-11]. However, 
there are few studies exploring the direct effects of obesity on 
the LDL-C lowering action of statin. The poor response to statin 
therapy in patients with high BMIs might not be due simply to 
greater fat mass, but also due to higher insulin resistance and 
more severe dyslipidemia leading to high triglyceride and apo-
lipoprotein B levels. Comparisons of the LDL-C lowering ef-
fects of statin between groups with high and low BMIs should 
be performed alongside concurrent analyses of triglyceride 
and HDL-C levels.
  Although their results require further discussion, Kim et 
al.’s study is important because the LDL-C lowering effects of 
10 mg atorvastatin regimens, which is one of the most often 
prescribed statin regimens in Korea, was assessed for relatively 
long duration of follow-up period in Korean type 2 diabetes 
patients. I greatly appreciate the efforts of the authors in per-
forming such an interesting study and in publishing their work 
in this journal. 
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